OPENACT: PHASE 2, OPEN-LABEL STUDY OF SIPULEUCEL-T IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC)

被引：0
作者：
Corman, J. [1 ]
Dawson, N. [2 ]
Hall, S. [3 ]
Nabhan, C. [4 ]
Ferrari, A. [5 ]
Armstrong, A. J. [6 ]
Murdock, M. I. [7 ]
Stewart, F. [8 ]
Sheikh, N. [9 ]
Petrylak, D. P. [10 ]
机构：
[1] Virginia Mason Med Ctr, Seattle, WA 98101 USA
[2] Georgetown Univ, Washington, WA USA
[3] Mt Sinai Sch Med, New York, NY USA
[4] Advocate Lutheran Gen Hosp, Park Ridge, IL USA
[5] NYU, Ctr Canc, New York, NY USA
[6] Duke Univ, Duke Canc Inst, Durham, NC USA
[7] Murdock Urol Associates, Urol, Greenbelt, MD USA
[8] Dendreon Corp, Biometr, Seattle, WA USA
[9] Dendreon Corp, Clin Immunol, Seattle, WA USA
[10] Columbia Univ, Med Ctr, New York, NY USA
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：311 / 311
页数：1
相关论文
共 50 条
  • [21] SIPULEUCEL-T IN AFRICAN AMERICANS: A SUBGROUP ANALYSIS OF THREE PHASE 3 TRIALS OF SIPULEUCEL-T IN METASTATIC CASTRATE RESISTANT PROSTATE CANCER
    McLeod, David G.
    Quinn, David I.
    Cullen, Jennifer
    Whitmore, James B.
    JOURNAL OF UROLOGY, 2012, 187 (04) : E388 - E388
  • [22] Race-Related Differences in Sipuleucel-T Response among Men with Metastatic Castrate-Resistant Prostate Cancer
    Heath, Elisabeth I.
    Thakur, Archana
    Chen, Wei
    Hwang, Clara
    Paller, Channing J.
    Cackowski, Frank C.
    Boerner, Julie L.
    Heilbrun, Lance
    Smith, Melanie P.
    Schalk, Dana L.
    Schienschang, Amy
    Whitaker, Sarah A.
    Polend, Amanda
    Smith, Daryn
    Vaishampayan, Ulka N.
    Dickow, Brenda
    Lum, Lawrence G.
    CANCER RESEARCH COMMUNICATIONS, 2024, 4 (07): : 1715 - 1725
  • [23] A comparison of sipuleucel-T (sip-T) product parameters from two phase III studies: PROVENT in active surveillance prostate cancer and IMPACT in metastatic castrate-resistant prostate cancer (mCRPC)
    Ross, Ashley
    Armstrong, Andrew J.
    Pieczonka, Christopher M.
    Bailen, James L.
    Tutrone, Ronald F.
    Cooperberg, Matthew R.
    Pavlovich, Christian P.
    Renzulli, Joseph F.
    Haynes, Heather
    Sheikh, Nadeem Anwar
    Shore, Neal D.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [24] Complete Biochemical Response (Prostate Specific Antigen) to Sipuleucel-T in Metastatic Castrate-Resistant Prostate Cancer: A Case Report With Docetaxel Chemotherapy Administered Just Before Sipuleucel-T
    McNamara, Megan
    Berry, William
    CLINICAL GENITOURINARY CANCER, 2015, 13 (05) : E361 - E364
  • [25] Randomized phase II study of sipuleucel-T (SipT) with or without radium-223 (Ra223) in men with asymptomatic bone-metastatic castrate-resistant prostate cancer (mCRPC)
    Marshall, Catherine Handy
    Park, Jong Chul
    DeWeese, Theodore L.
    King, Serina
    Afful, Michaella
    Hurrelbrink, Julia
    Manogue, Charlotte
    Cotogno, Patrick
    Moldawer, Nancy P.
    Barata, Pedro C.
    Drake, Charles G.
    Posadas, Edwin M.
    Armstrong, Andrew J.
    Sartor, A. Oliver
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [26] Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer
    Gardner, Thomas A.
    Elzey, Bennett D.
    Hahn, Noah M.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2012, 8 (04) : 534 - 539
  • [27] Randomized phase II trial of sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-t alone in patients with metastatic castrate resistant prostate cancer
    Twardowski, Przemyslaw
    Wong, Jeffrey Y. C.
    Pal, Sumanta K.
    Frankel, Paul Henry
    Franklin, Kelly
    Junqueira, Maribel
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [28] A phase II, multicenter, randomized, open-label study to evaluate the safety and tolerability of proxalutamide (GT0918) in subjects with metastatic castrate-resistant prostate cancer (mCRPC).
    Zhou, Tie
    Ye, Dingwei
    Sun, Zhongquan
    Meng, Qinggui
    He, Dalin
    Shi, Guowei
    Jin, Jie
    Sun, Weibing
    Chen, Lijun
    Liu, Ben
    Wang, Jingen
    Cheng, Jiwen
    Hu, Zhiquan
    Yang, Yong
    Song, Xishuang
    Wang, Yinhuai
    Fu, Cheng
    Zhou, Qiaoxia
    Tong, Youzhi
    Sun, Ying-Hao
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [29] Development of sipuleucel-T: Autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer
    Sims, Robert B.
    VACCINE, 2012, 30 (29) : 4394 - 4397
  • [30] Time to disease-related pain after sipuleucel-T in asymptomatic patients with metastatic castrate-resistant prostate cancer (mCRPC): Results from three randomized phase III trials
    Small, E. J.
    Higano, C. S.
    Kantoff, P. W.
    Whitmore, J. B.
    Frohlich, M. W.
    Petrylak, D. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345